イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspen pharma trading ltd - azathioprine - oral tablet - 50mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - azathioprine - oral tablet - 50mg

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - calcium folinate, quantity: 54 mg (equivalent: folinic acid, qty 50 mg) - injection, solution - excipient ingredients: sodium chloride; water for injections - neutralising the immediate toxic effects of folic acid antagonists, eg methotrexate. treatment of megaloblastic anaemias due to folic acid deficiency, eg in sprue, malnutrition, pregnancy, infancy, liver disease and malabsorption syndromes. folinic acid rescue, ie using calcium folinate in conjunction with folic acid antagonists, eg methotrexate, to minimise systemic toxicity. indications as at 13 jan 05 : leucovorin calcium has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions. leucovorin calcium has also shown good results in reducing the toxicity and circumventing the effect of folic acid antagonists, if therapeutically desired.

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - azathioprine - oral tablet - 50mg

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - mercaptopurine monohydrate - tablet - 50 milligram(s) - mercaptopurine

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - azathioprine - oral tablet - 50mg

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - mercaptopurine monohydrate - tablet - 50 milligram(s) - mercaptopurine

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

stason pharmaceuticals, inc. - mercaptopurine (unii: e7wed276i5) (mercaptopurine anhydrous - unii:pkk6muz20g) - purinethol is indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (all) as part of a combination chemotherapy maintenance regimen. none. purinethol can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . pregnant women who receive mercaptopurine have an increased incidence of miscarriage and stillbirth (see data) . advise pregnant women of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. women receiving mercaptopurine in the first trimester of pregnancy have an increased incidence of miscarriage; the risk of malformation in offspring surviving first trimester exposure is not known. in a series of 28 women receiving mercaptopurine after the first trimester of pregnancy, 3 mothers died prior to delivery, 1 delivered a stillborn child, and 1 aborted; there were no cases of macroscopically abnormal fetuses. mercaptopurine was embryo-lethal and teratogenic in several animal species (rat, mouse, rabbit, and hamster) at doses less than the recommended human dose. there are no data on the presence of mercaptopurine or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with purinethol and for 1 week after the last dose. purinethol can cause fetal harm when administered to pregnant women [see use in specific populations (8.1)] . verify the pregnancy status in females of reproductive potential prior to initiating purinethol  [see use in specific populations (8.1)] . advise females of reproductive potential to use effective contraception during treatment with purinethol and for 6 months after the last dose. based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with purinethol and for 3 months after the last dose [see nonclinical toxicology (13.1)] . based on findings from animal studies, purinethol can impair female and male fertility [see nonclinical toxicology (13.1)] . the long-term effects of mercaptopurine on female and male fertility, including the reversibility have not been studied. safety and effectiveness of purinethol has been established in pediatric patients. use of purinethol in pediatrics is supported by evidence from the published literature and clinical experience. symptomatic hypoglycemia has been reported in pediatric patients with all receiving mercaptopurine. reported cases were in pediatrics less than 6 years of age or with a low body mass index. clinical studies of mercaptopurine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or another drug therapy. use the lowest recommended starting dosage for purinethol or increase the dosing interval to every 36-48 hours in patients with renal impairment (clcr less than 50 ml/min). adjust the dose to maintain absolute neutrophil count (anc) at a desirable level and for adverse reactions [see dosage and administration (2.3)] . use the lowest recommended starting dosage for purinethol in patients with hepatic impairment. adjust the dose to maintain absolute neutrophil count (anc) at a desirable level and for adverse reactions [see dosage and administration (2.3)] .

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

fontus health limited - mercaptopurine - tablet - 50 milligram(s) - purine analogues; mercaptopurine

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - mercaptopurine monohydrate 50mg; mercaptopurine monohydrate 50mg - tablet - 50 mg - active: mercaptopurine monohydrate 50mg excipient: lactose monohydrate magnesium stearate maize starch stearic acid active: mercaptopurine monohydrate 50mg excipient: lactose monohydrate magnesium stearate maize starch stearic acid - puri-nethol is indicated for the treatment of acute leukaemia. it may be utilised in remission induction and is particularly indicated for maintenance therapy in: · acute lymphoblastic leukaemia; · acute myelogenous leukaemia.